spacer
home > ebr > Autumn 2014
PUBLICATIONS

European Biopharmaceutical Review

ebr
Autumn 2014

   
Text
PDF
Editor’s Letter

Deborah O’Neil ponders the recent Ebola outbreak and discusses some of this edition’s focus features.
 
view
download pdf
Science and Innovation
Mass Spectrometry

Molecular Weight


Intact mass analysis has the benefits of minimal sample preparation, high-speed analysis and minor method-induced modifications. Nicholas Michael and Pat Easton at Reading Scientific Services Ltd explain.
 
view
download pdf
Column Technology

HPLC’s Golden Jubilee: Part 2


In the second of a two-part series, Ronald Majors from Agilent Technologies reviews the progress of highperformance liquid chromatography over the last 50 years and considers what the future holds.
 
view
download pdf
bullet
BioResearch and Innovation
Nanotechnology

On Target


A sound understanding of biological responses, combined with close coordination of drug delivery mechanisms and particle toxicology, are essential for the safe and effective use of nanoparticles in drug delivery, advises Aiswariya Chidambaram at Frost & Sullivan.
 
view
download pdf
BioDevelopment
Transient Gene Expression

Shifting the Balance

Stable cell line generation can be costly in terms of time, labour and money. Karen Donato, Krista Steger and Meg Duskin at MaxCyte, Inc weigh up transient gene expression as an alternative.
 
view
download pdf
Q&A: Cell Line Development

Path to Progress


FUJIFILM Diosynth Biotechnologies’ Alison Porter tells EBR what must be considered when creating a new host cell line, and gives tips on how to save future development time and meet production requirements.



 
view
download pdf
Mammalian Cell Culture

Testing Times


Universitat Autònoma de Barcelona’s Francesc Gòdia recommends the design of experiments approach as a means to accelerate the screening of effi cient compounds and the corresponding optimal conditions.
 
view
download pdf
bullet
Legal, Regulatory and Public Policy
Regulatory Challenge

Rapid response


The growing advances in genomics and how this area fi ts in with personalised medicine is uncharted territory, particularly for regulatory agencies. Regina Au at BioMarketing Insight contemplates the current approval processes.


 
view
download pdf
Personalised Medicine

Individual Focus

With molecular profi ling allowing for patient-specific therapeutic strategies, the need to encourage research must be balanced against demands for privacy protection, reports Emma Naks at EBR.
 
view
download pdf
EU Legislation

In Harmony?


Shuna Mason from CMS points out that although recent legislative changes reveal an intention to promote personalised medicine within the EU, there is still some way to go in harmonising regulation.
 
view
download pdf
bullet
BioDevelopment and Regulatory
Temperature Standardisation

Playing it Cool


Rolf Ehrhardt and Maria Thompson from BioCision raise awareness of the importance of temperature standardisation in the field of cell biology, and evaluate current practice.
 
view
download pdf
bullet
INTERVIEW
Industry Insight

Hot Spot


EBR talks to Frédéric Druck at BioWin about Wallonia, Belgium, and why this region is proving a favourite for companies looking to focus on immunology R&D.
 
view
download pdf
bullet
INDUSTRY DYNAMICS
In Brief

A Tale of Two Cities


Despite their common heritage, the US and UK have evolved two distinct approaches to the provision of healthcare and managing costs on a national scale. Emile Bellot explores further.
 
view
download pdf
bullet
BUSINESS STRATEGY
Industry Collaboration

Better Together


Pharma companies must realise that productivity does not exist only in delivering effective new compounds, but also in playing a responsive and active part alongside others, reason Peter Wagner and Christoph Schnorr of Quintiles.


 
view
download pdf
Open Innovation

Compound Interest


Simon MacKenzie and Sylviane Boucharens at BioAscent Discovery Ltd suggest why using corporate compound collections as a shareable asset is both promising and valuable.
 
view
download pdf
Clinical Supply Partnerships

Need for Speed

Martin Lamb and Claudia Williams at Biotec Services International propose partnering with a clinical supply business to help cut costs and reduce time to market.
 
view
download pdf
bullet
BIOIMAGING
Drug Development

Eye for Success


MPI Research’s Scott Haller believes that contemporary molecular imaging offers pharma a set of tools capable of dramatically de-risking clinical drug development.
 
view
download pdf
Kinetic Modelling

Made to Measure


When it comes to oncology imaging, volumes can allow for a more complete picture, as well as a sophisticated estimation of tumour growth. David Raunig, Gregory Goldmacher and Stephanie Owens at ICON reflect.
 
view
download pdf
   
spacer


Published quarterly in
January, April,
July, and October

News and Press Releases

Northway Biotechpharma enters into Development and Manufacturing Agreement with Synklino

Vilnius, Lithuania, and Copenhagen, Denmark – December 18th 2019 – Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Synklino, a company active in developing a therapeutic protein based therapy as treatment for cytomegalovirus (CMV) infection, announced today that they entered into a Development and Manufacturing Agreement for the recombinant fusion protein SYNx, which Synklino aims to bring into clinical trials.
More info >>

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

23-26 March 2020, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 23 – 26 March 2020. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement